

1 **Spatial inequities in access to medications for treatment of opioid use disorder highlight scarcity of**
2 **methadone providers under counterfactual scenarios**

3

4 Eric Tatar^{1,2*}, Qinyun Lin³, Jonathan Ozik^{1,2}, Marynia Kolak³, Nicholson Collier^{1,2}, Dylan Halpern³, Luc
5 Anselin³, Harel Dahari⁴, Basmattee Boodram⁵, and John Schneider⁶

6

7 ¹Consortium for Advanced Science and Engineering, University of Chicago, Chicago, IL, USA.

8 ²Decision and Infrastructure Sciences, Argonne National Laboratory, Lemont, IL, USA.

9 ³Center for Spatial Data Science, University of Chicago, Chicago, IL, USA.

10 ⁴The Program for Experimental & Theoretical Modeling, Division of Hepatology, Department of
11 Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA.

12 ⁵Division of Community Health Sciences, School of Public Health, University of Illinois at Chicago,
13 Chicago, IL, USA.

14 ⁶University of Chicago Medicine, Department of Infectious Disease, Chicago, IL, USA.

15

16 ***Corresponding author:**

17 Email: tatar@anl.gov (ET)

18

19 **Declarations of competing interest:** None of the authors have any financial interest or conflict of
20 interest related to this research.

21

22 **Key words:** MOUD; opioid use disorder; persons who inject drugs; agent-based modeling; methadone

23 **ABSTRACT**

24 Access to treatment and medication for opioid use disorder (MOUD) is essential in reducing opioid use
25 and associated behavioral risks, such as syringe sharing among persons who inject drugs (PWID). Syringe
26 sharing among PWID carries high risk of transmission of serious infections such as hepatitis C and HIV.
27 MOUD resources, such as methadone provider clinics, however, are often unavailable to PWID due to
28 barriers like long travel distance to the nearest methadone provider and the required frequency of clinic
29 visits. The goal of this study is to examine the uncertainty in the effects of travel distance in initiating and
30 continuing methadone treatment and how these interact with different spatial distributions of
31 methadone providers to impact co-injection (syringe sharing) risks. A baseline scenario of spatial access
32 was established using the existing locations of methadone providers in a geographical area of
33 metropolitan Chicago, Illinois, USA. Next, different counterfactual scenarios redistributed the locations of
34 methadone providers in this geographic area according to the densities of both the general adult
35 population and according to the PWID population per zip code. We define different reasonable
36 methadone access assumptions as the combinations of short, medium, and long travel distance
37 preferences combined with three urban/suburban travel distance preference. Our modeling results show
38 that when there is a low travel distance preference for accessing methadone providers, distributing
39 providers near areas that have the greatest need (defined by density of PWID) is best at reducing syringe
40 sharing behaviors. However, this strategy also decreases access across suburban locales, posing even
41 greater difficulty in regions with fewer transit options and providers. As such, without an adequate
42 number of providers to give equitable coverage across the region, spatial distribution cannot be optimized
43 to provide equitable access to all PWID. Our study has important implications for increasing interest in
44 methadone as a resurgent treatment for MOUD in the United States and for guiding policy toward
45 improving access to MOUD among PWID.

46 INTRODUCTION

47 Access to treatment and medication for opioid use disorder (MOUD) is essential in reducing behavioral
48 risks for HIV and HCV infection and overdose associated with injection drug use [1–3]. In addition to
49 individual competing priorities (e.g., unstable housing, childcare), barriers to access to MOUDs among
50 people who inject drugs (PWID) may include structural factors (e.g., drug use-related stigma [4], long
51 travel distances, or policy barriers [5]). Historical, socioeconomic, racial, and other structural factors
52 influence both availability and perception of MOUDs [5–7]. Furthermore, there is a high degree of
53 variability in individual MOUD pharmacology, delivery, and patient preference. As a golden standard to
54 address MOUD access inequities, MOUDs should be available in all communities to facilitate treatment
55 individualization and treatment support retention. As such, understanding access to MOUDs, health
56 services, and other harm reduction services (e.g., syringe service programs) is critical to defining risk
57 environment landscapes that affect fatal and nonfatal overdoses and HIV and HCV infections related to
58 injection drug use.

59
60 Effective prevention and treatment strategies exist for opioid use disorder (OUD) but are highly
61 underutilized in the United States. Indeed, only a small fraction (11%) who need MOUD received it in 2020
62 [8]. Methadone, a synthetic opioid agonist that eliminates withdrawal symptoms and relieves drug
63 cravings by acting on opioid receptors in the brain, is the medication with the longest history of use for
64 OUD treatment, having been used since 1947. A large number of studies support methadone's
65 effectiveness at reducing opioid use [9], but have also shown methadone access disparities along racial,
66 ethnic socio-demographics, and geographic location. While expedient access to methadone maintenance
67 treatment is critical to preventing overdose death [10], at this time its provisioning is restricted to federally
68 licensed opioid treatment program (OTP) locations, which tend to reflect carceral approaches to
69 treatment such as strict patient surveillance, limited flexibility in medication schedules, and high

70 frequency of travel to OTP locations [5,11]. While access to other MOUDs such as buprenorphine has
71 increased across the US due in part to fewer administrative restrictions, people with OUD deserve options
72 for treatment and many patients prefer methadone even with the geographic access barriers: a factor
73 that motivates the current analysis [12]. This has led to a resurgence in efforts to remove administrative
74 restrictions on clinics and providers to provide methadone to treat OUD among people who use drugs [5].

75

76 The goal of this study is to examine the uncertainty in the effects of travel distance in initiating and
77 continuing methadone treatment for OUD and how these uncertainties interact with different spatial
78 distributions of methadone providers to impact co-injection (syringe sharing) risks among PWID.
79 Behavioral risk mitigation (i.e., reduction in syringe sharing) is often a function of the complex interplay
80 of historical, sociological, and structural factors, resulting in nuanced patterns that reflect underlying
81 social and spatial inequities. Research on access to primary health services often cite a preference for a
82 less than 30-minute travel time for individuals seeking care [13,14], though a recent survey on driving
83 times to OTPs showed that almost 18% of the US population would have driving times in excess of 30
84 minutes to the nearest OTP, and almost 37% of individuals in rural counties experiencing OTP drive times
85 over an hour [15]. Currently, more than a third of continental U.S. zip codes are more than an hour away
86 from treatment, and access to methadone providers remains worse than other MOUD types (ex.
87 buprenorphine and naltrexone) [16]. Providing transportation services has been shown to improve
88 treatment retention for methadone maintenance programs and outpatient drug-free programs [17] and
89 transportation costs have been shown to be a significant factor in travel to OTPs [15]. Minoritized
90 racial/ethnic status has been associated with admission delays for outpatient methadone treatment [6]
91 and reduced likelihood of being offered pharmacologic support for recovery [18] – though once engaged
92 in treatment, have similar retention rates to the majority of clients [19]. At the same time, minoritized
93 groups may prefer accessing treatment services within primary care settings versus specialty mental

94 health clinics [20]. While geographic access to treatment is crucial, access is a multidimensional concept
95 that can be deconstructed into the components of availability, accommodation, affordability, and
96 acceptability [21]. For persons with OUD, access is especially complex because of the interplay of MOUD
97 resource scarcity and drug use stigma, as patients experiencing stigma from MOUD providers are less
98 likely to return [22].

99
100 Measuring spatial access to public resources like OTPs must consider the frequency of resource utilization
101 and the mode of transit to the resource [23]. Travel hardships, including extended distances, longer travel,
102 and interstate commute, have been considered as the most common accessibility barriers for people who
103 seek care from distant providers, especially for persons in rural areas where public transportation is
104 limited [15,24–27]. Most existing studies focus on *actual* distance to MOUD locations and very few have
105 studied what is the *ideal* distance (or travel time) preferences to ensure accessibility. The effect of travel
106 hardships on accessibility is most critical for methadone considering the need for daily dosing. Increased
107 distance to treatment can impede daily attendance as shown in a recent study of patients receiving MOUD
108 treatment that found patients residing 10 miles from the treatment facility were more likely to miss doses
109 compared to those who lived within 5 miles [28]. Conventional interventional trials test whether
110 modification of spatial factors is needed, but often difficult and costly to implement.

111
112 There is a need for more rapid approaches to assessing and translating spatial epidemiologic findings to
113 practical real-world interventions that benefit proven, yet underutilized interventions such as methadone
114 treatment for MOUD. We examine the impact of methadone provider distribution on syringe sharing
115 among PWID from Chicago, IL, USA and the surrounding suburbs using a validated agent-based model
116 (ABM) (Hepatitis C Elimination in Persons Who Inject Drugs or HepCEP) [2]. Our modeling approach
117 accounts for uncertainties in how individuals perceive access to methadone providers and how that

118 perception affects their decisions to initiate and adhere to MOUD treatment. As such, we employ a robust
119 decision making perspective [29] to capture the effects of different methadone provider distribution
120 approaches across these uncertainties.

121

122 **METHODS**

123 **HepCEP Model**

124 The current study extends our previous work on simulating the PWID population in Chicago and the
125 surrounding suburbs, Illinois, USA, including drug use and syringe sharing behaviors, and associated
126 infection dynamics [2,30]. The demographic, behavioral, and social characteristics of the PWID population
127 is generated using data from five empirical datasets on metropolitan Chicago (urban and suburban) area
128 PWID that is previously described [30]. In brief, this includes data from a large syringe service program
129 (SSP) enrollees (n=6,000, 2006-13) [31], the IDU data collection cycles of the National HIV Behavioral
130 Surveillance (NHBS) survey from 2009 (n=545) [32] and 2012 (n=209) [33], and a social network and
131 geography study of young (ages 18-30) PWID (n=164) [34]. Data analyses from these sources is used to
132 generate attributes for each of the estimated 32,000 PWID in the synthetic population for metropolitan
133 Chicago [35] in the model and includes: age, age of initiation into injection drug use, gender,
134 race/ethnicity, zip code of residence, HCV infection status, drug sharing network degree, parameters for
135 daily injection and syringe sharing rates, and harm reduction/syringe service program (SSP) enrollment
136 [30]. PWID agents may leave the population due to age-dependent death or drug use cessation and are
137 replaced with new PWID sampled from the input data set to maintain a nearly constant population size
138 of 32,000 for the entire course of the simulation.

139

140 Syringe sharing among PWID is modeled in HepCEP via dynamic syringe sharing networks. Network
141 formation is determined by the probability of two PWID encountering each other in their neighborhood

142 of residence and within the outdoor drug market areas in Chicago that attracts both urban and non-urban
143 PWID for drug purchasing and utilization of SSPs that are also located in the same areas [36]. The methods
144 used to calculate network encounter rates, establishment processes, and removal of networks have been
145 described previously [30]. Each modeled individual has an estimated number of in-network PWID partners
146 who give syringes to the individual and out-network PWID partners who receive syringes from the
147 individual. The network edge direction determines the flow of contaminated syringes between
148 individuals, and thus the direction of disease transmission. The network evolves over time, and during the
149 course of the simulation some connections (ties) may be lost, while new ties form, resulting in an
150 approximately constant network size.

151
152 MOUD treatment enrollment is modeled in two steps. First, there is an unbiased awareness of MOUD
153 resources by PWID, capturing the knowledge that agents possess about the existence of a methadone
154 provider. The annual target awareness rate, defined as the total annual awareness as a fraction of the
155 total population, is a model parameter with a constant value of 90%. Thus, over the course of a year, 90%
156 of the PWID population will be made aware of MOUD treatment and, subsequently decide whether to
157 engage in MOUD treatment. The total PWID target MOUD treatment awareness for a single day is
158 determined by the daily mean treatment awareness, which is the total PWID population multiplied by the
159 annual treatment awareness parameter / 365. The daily awareness target is sampled from a Poisson
160 distribution using the daily mean treatment awareness.

161
162 PWID that receive MOUD treatment experience a reduction in the number of daily drug injections, which
163 is determined by multiplying the PWID's baseline pre-MOUD daily drug injection frequency by a reduction
164 multiplier sampled from a uniform distribution from 0 to 0.25 [37]. Thus, the mean reduction in daily

165 injection frequency is 87% when on MOUD treatment compared to when not on MOUD. Reduction in
166 daily injection frequency reduces the number of syringe sharing episodes with other infected individuals.
167

168 **Reasonable Geographic Access Assumptions**

169 Our approach to model the initiation and continuation of MOUD treatment incorporates multiple aspects
170 of access to care: 1) the travel distance to the nearest methadone provider from the PWID place of
171 residence, 2) the frequency of clinic visits, and 3) racial/ethnic inequalities to treatment as represented
172 by the geospatial heterogeneity of the PWID population demographics. PWID first decide to enroll in
173 MOUD treatment and then subsequently decide to continue treatment every 7 days, a duration chosen
174 to reflect the average frequency of clinic visits for the treatment over time. Average overall treatment
175 duration for methadone is obtained from literature to be 150 days [38] and different urban and non-urban
176 travel distance preferences to the nearest methadone provider are used by PWID to determine if they will
177 or will not enroll in MOUD treatment (Table 1). The probability that a PWID will enroll in MOUD treatment
178 is greater when the treatment travel distance is below the travel distance preference.

179 **Table 1.** Travel distance to methadone provider preferences used for reasonable geographic access
180 assumptions. The table represents six different possible combinations of low, medium, and high travel
181 distance preferences considering three urban/suburban distance preference combinations for each low,
182 medium, high distance preference pair with a maximum distance limit, and three corresponding low,
183 medium, and high distance preference pairs with no maximum distance limit.

Travel Distance Preference	Travel Distance to Methadone Provider (miles)			
	With Maximum Distance Limit		No Maximum Distance Limit	
	Urban	Suburb/Rural	Urban	Suburb/Rural
Low	1 (max: 15)	5 (max: 60)	1	5
Medium	2 (max: 15)	10 (max: 60)	2	10
High	5 (max: 15)	20 (max: 60)	5	20

184 We define six different possible combinations of low, medium, and high travel distance preferences
185 considering three urban/suburban distance preference combinations for each low, medium, high travel
186 distance preference pair with a maximum travel distance preference, and three corresponding low,
187 medium, and high travel distance preferences pairs with no maximum distance preference (Table 1). In
188 the cases with maximum preferences, the individuals will not be able to access treatment if the provider
189 is farther away than the maximum preferred travel distance.

190
191 To approximate reasonable geographic access, the travel distance in miles from zip code centroid to the
192 nearest methadone provider is calculated using the *sf* package in R (version 4.0.2) [39]. Methadone
193 treatment requires frequency of visits comparable to that of people’s grocery shopping (daily or weekly)
194 [40,41], and travel distances of 1 mile (urban) and 10 miles (suburban/rural) areas is reasonable for
195 community members, respectively, to their grocery stores. Because of the scarcity of methadone
196 providers, we extend the urban reasonable travel distance preference to 2 miles. Published findings
197 indicate that access to mental health treatment within 10 miles is associated with greater attendance in
198 persons with OUD [42]. Accordingly, the travel distance preference of “reasonable geographic access” to
199 the methadone provider is set at 2 miles in urban areas, which approximates a 30-minute walking
200 distance, and for suburban and rural areas, the travel distance preference is set at 10 miles (Table 1).

201
202 As there is limited information on how geographic access affects individuals’ decision to seek treatment,
203 an additional layer of uncertainty is introduced via penalties on individuals’ probability of getting
204 treatment when the geographic travel distance exceeds the reasonable access distance preference but is
205 below the maximum distance limit. If the travel distance exceeds the preference, the per-decision
206 probability of treatment is lower (by a factor θ) than if the PWID is closer to the provider. Since θ is not
207 easily estimated, values are chosen ranging from 60% to 90% for this study, which represents broad per-

208 decision penalties for accessing locations beyond distance preferences. The base probabilities are
209 calculated by using the distribution of the PWID agent population under the actual spatial distribution of
210 methadone providers (see below) and under different preference scenarios to match the overall
211 methadone treatment duration values. Each penalty level is combined with each of the six travel distance
212 preference combinations in Table 1, resulting in 18 separate parameter combinations, or reasonable
213 access assumptions.

214

215 **Spatial Distribution of Methadone Providers**

216 **MOUD Provider Data**

217 This study includes data on methadone maintenance MOUD providers in Chicago and the surrounding
218 suburbs, which we define as the 298 zip codes from Cook County (i.e., the most populous county in Illinois
219 and includes Chicago) and the five collar counties that border Cook, which are also the next five most
220 populous counties in the state. We include providers beyond these boundaries for the state of Illinois to
221 provide context in interpretation, though only perform simulations and evaluate scenarios within these
222 boundaries. A total of 81 Illinois providers are identified by specifying “methadone maintenance” from
223 the Substance Abuse and Mental Health Service Administration (SAMHSA) Behavioral Health Treatment
224 Service Locator (derived from the 2019 National Survey of Substance Abuse Treatment Service) [43].

225

226 **Counterfactual Methadone Provider Spatial Distributions**

227 To study how the spatial distribution of methadone providers affects syringe sharing behaviors among
228 PWID, three counterfactual distributions are generated to spatially redistribute methadone provider
229 locations. That is, the geographic locations of methadone providers are changed and re-evaluated for
230 accessibility to those providers. In all scenarios, the total number of all methadone providers in Illinois is
231 assumed to be constant ($n = 81$).

232 **Spatially random:** MOUD treatment locations are randomly distributed within the study area (298 zip
233 codes in Cook and five collar counties) and other areas (1085 zip codes) in Illinois. The total number of
234 modelled methadone providers in Illinois remains unchanged; only the location of these resources
235 changes. This distribution provides a useful null hypothesis of spatial randomness that can be
236 benchmarked against actual geographic distribution of resources, as well as alternate counterfactual
237 distributions.

238
239 **Need-based 1:** Methadone provider locations are assigned proportionally to the adult population (age 18-
240 39) within each zip code which results in more methadone providers assigned to zip codes with larger
241 adult populations. The Hamilton (largest remainder) method [44] is used to calculate the number of
242 methadone providers assigned to each zip code and to ensure that each area was assigned an integer
243 number of methadone providers. Specifically, methadone providers are first allocated to each zip code
244 proportional to the local at-risk population. The result for each zip code consists of an integer part plus a
245 fractional remainder, or in some cases, only a fractional remainder. Each zip code is first allocated an
246 integer number of providers. This leaves some providers unallocated. The zip codes are then ranked based
247 on the fractional remainders: one additional methadone provider is added to the zip code areas ranking
248 the highest until all providers are allocated.

249
250 **Need-based 2:** In this distribution, methadone providers are assigned proportionally to the total PWID
251 population [30] for each zip code. The difference between *Need-based 1* and *Need-based 2* is how the
252 need for methadone within each zip code area is estimated. Need-based 2 is potentially better reflects
253 local geographic needs as the PWID population likely represents a closer approximation for the need for
254 methadone providers than an area's entire adult population.

255

256 **Outcome: Syringe sharing**

257 The reduction in annual syringe sharing events among PWID who are adherent to methadone treatment
258 relative to a baseline scenario without methadone availability is investigated as the main outcome of
259 interest of the simulation studies. Syringe sharing reduction is calculated for each of the 18 reasonable
260 access assumptions in each of the three counterfactual methadone provider distributions, along with the
261 actual provider distribution. A baseline simulation is first conducted to determine the number of annual
262 syringe sharing events in each zip code when PWID have no awareness of methadone providers, and do
263 not enroll in MOUD treatment. The baseline is not sensitive to provider distribution or travel distance
264 preference since no MOUD treatment occurs.

265
266 For each combination of reasonable access assumption and provider distribution, the syringe sharing
267 reduction metric is defined as the difference in the number of annual syringe sharing events in each zip
268 code when PWID are aware of methadone providers, relative to the baseline. The HepCEP model is run
269 for a 20-year period starting in 2010 through simulated year 2030. The total number of syringe sharing
270 events in each zip code is tabulated only for year 2030, resulting in the metrics for annual syringe sharing
271 reduction. The simulation time frame is based on the need to initialize the model using population data
272 calibrated to year 2010, and to allow the model population and network dynamics to stabilize, as has been
273 done in prior studies [22,24].

274
275 A total of 1,440 simulations were conducted using high-performance computing workflows implemented
276 with the EMEWS framework [45]. The 1,440 runs include 20 stochastic replicates for each of the 72
277 parameter sets, where each parameter set corresponds to the four provider spatial distributions for each
278 of the 18 reasonable access assumptions. We report the mean number of syringe sharing episodes across

279 the 20 stochastic replicates. The simulation experiments were executed on the Bebop cluster run by the
280 Laboratory Computing Resource Center at Argonne National Laboratory.

281
282 Annual syringe sharing reduction relative to baseline (no MOUD) is aggregated across all zip codes to
283 produce a single scalar metric for each of the 72 parameter sets. We define a decision regret score to
284 represent the difference in syringe sharing reduction for each of the four spatial provider distributions,
285 relative to the spatial distribution with the largest reduction in syringe sharing, for each combination of
286 reasonable access assumptions. A decision regret score of zero represents the best outcome in terms of
287 reducing syringe across each of the four spatial provider distributions, for a specific combination of
288 reasonable access assumptions. Conversely, a high regret score means that the scenario had a significantly
289 larger number of syringe sharing episodes relative to the best scenario with the fewest number of syringe
290 sharing episodes.

291
292 The 75th-percentile of the regret score distribution for each of the four provider spatial distribution
293 scenarios is used to evaluate the robustness for each spatial strategies, i.e., adequate performance over
294 a wide range of possible ground truths and decision-making uncertainties.

295

296 **RESULTS**


297 **Spatial access to methadone providers under different reasonable geographic access assumptions**

298 Figure 1 provides a geographic illustration of whether each zip code minimum travel distance to a
299 methadone provider is within the travel distance preference of reasonable geographic access (Table1),
300 underlying different assumptions of what is the ideal distance to ensure accessibility. The first, second,
301 and third row in Figure 1 corresponds to the low, middle, and high travel distance preferences,
302 respectively in Table 1. For each travel distance preference (each row in Figure 1), the four figures


303 (columns in Figure 1) show each zip code's accessibility to the nearest methadone provider under the
304 actual spatial distribution of providers and three counterfactual spatial distributions.

305
306 Comparing the actual provider spatial distribution with the two need-based distributions (Figure 1,
307 column-wise), we identify areas where the need for methadone providers is high while the spatial access
308 to providers is limited. For example, some areas in Chicago have high need but few providers, and
309 accessibility to methadone providers are improved in the two need-based counterfactual distributions.


310
311 Comparing across rows in Figure 1, more zip codes have better spatial access to methadone providers as
312 we assume a higher travel distance preference (i.e., people are able and willing to travel longer distances).
313 This preference does not account for transit barriers such as travel time and access to public transit
314 infrastructures, vehicles, as well as the financial cost of transit. Under the low travel distance preference
315 that likely reflects real-world barriers to transit, few areas have reasonable geographical access to
316 methadone providers. Therefore, simply redistributing methadone providers spatially may not provide
317 better access when the number of individual providers is limited.



Low Preference Assumption: 1 mile urban, 5 miles suburban



Medium Preference Assumption: 2 miles urban, 10 miles suburban



High Preference Assumption: 5 miles urban, 20 miles suburban

- Spatially Accessible Zip Code Area
- Not Spatially Accessible Zip Code Area
- City of Chicago Boundary
- County Boundary

0 20 40 mi

Coordinate Reference System:
 EPSG: 3857, WGS 84/Pseudo-Mercator

318
 319
 320
 321
 322

323 **Figure 1. Spatial access to methadone providers for the actual scenario and three counterfactual**
324 **distribution scenarios, under varying travel distance preference assumptions.** Each dot represents the
325 location of a single methadone provider. City of Chicago and collar county borders are indicated. Spatial
326 access to methadone providers is calculated as distance to nearest provider to the center of each zip code
327 area; thus in the low travel distance preference assumption, zip codes areas are not identified as
328 accessible if there is no provider within a mile of its geographic center.

329
330

331 **Effects of spatial distribution of methadone providers on annual syringe sharing reduction by zip code**

332 Since the total number of methadone providers are fixed in this analysis, redistributing provider locations
333 in the counterfactual distributions relative to the actual distribution leads to some areas having a higher
334 reduction in syringe sharing events than others. The reduction in the number of annual syringe sharing
335 events (relative to baseline) in each zip code for the actual provider distribution (Figure 2, columns 1 and
336 5), under each reasonable access assumption reflect the zip code provider spatial accessibility in Figure 1.
337 The change in syringe sharing reduction by zip code, relative to the actual distribution, highlights the
338 effects of spatially redistributing methadone providers in each of the three counterfactual distributions
339 (Figure 2, columns 2-3 and 6-8). Blue colored zip codes indicate a larger reduction in annual syringe sharing
340 events than the actual distribution, while red colored zip codes indicate a lesser reduction in syringe
341 sharing than the actual distribution.

342

343 Simulation scenarios across a range of methadone provider location distributions and spanning the
344 spectrum from least optimistic reasonable access assumptions (Figure 2, upper rows, low travel distance
345 preference, maximum travel distance, and a penalty of 0.6.) to the most optimistic access assumptions
346 (Figure 2, lower rows, high travel distance preference, no travel distance maximum, and a penalty of 0.9)
347 demonstrate a high degree of spatial heterogeneity in the expected reduction in syringe sharing events
348 among PWID in Chicago, IL and surrounding suburbs.


Syringe Sharing Reduction (Actual Distribution)

A higher value (darker color) represents greater needle sharing reduction by ZIP Code.



Change in Syringe Sharing Reduction

The change difference in needle sharing reduction across three scenarios that modify the distribution of resources.



350 **Figure 2. Effects of reasonable access to methadone assumptions on syringe sharing events by zip code**
351 **for each scenario in Cook County IL and surrounding counties.** Columns 1 and 5 represent the reduction
352 in syringe sharing events for the actual spatial distribution of methadone providers, relative to the
353 baseline scenario without methadone. In the other columns, blue colored zip codes indicate a greater
354 reduction in syringe sharing events relative to the actual scenario, while red colored zip codes indicate a
355 lesser reduction in syringe sharing events relative to the actual scenario.


356

357 **Robustness of spatial methadone provider distributions in reducing annual syringe sharing events**

358 The spatial variation of syringe sharing reduction across reasonable access assumptions (Figure 2) reflects
359 heterogeneity in the PWID population both in terms of local population density, and in terms of drug use
360 behaviors and co-injection risks reflected in the underlying empirical population data used in the model.
361 Since the underlying individual PWID behaviors are difficult to observe in reality, optimizing provider
362 spatial distributions to reduce the number of syringe sharing events may not be an appropriate goal;
363 rather, the robustness of spatial distributions that perform well over a wide range of possible ground
364 truths and decision-making uncertainties are examined.

365

366 Figure 3 provides a visual representation of the regret scores for the annual reduction in syringe sharing
367 events for each of the 18 reasonable access assumptions, grouped by the four spatial distributions of
368 methadone providers (Supporting Information Tables S1, S2). Each point in Figure 3 represents the regret
369 score for each of the reasonable access assumptions, color coded by travel distance preference (Table1).
370 Given the definition of regret scores, lower values represent a more ideal outcome (less regret) for a
371 particular reasonable access assumption, i.e., values of zero indicate that the spatial provider distribution
372 had the largest reduction in syringe sharing events for the indicated reasonable access assumption.
373 Vertical box plots for each spatial provider distribution in Figure 3 provide the median, 25th and 75th
374 percentiles for regret score.



375
376 **Figure 3. Regret score of annual reduction in needle sharing by travel distance preference and spatial**
377 **distribution of methadone providers.** Each dot represents the regret score for each of the 18 reasonable
378 access assumptions (three travel distance preferences with and without maximum distance plus three
379 distance penalty values). Vertical box plots for each spatial provider distribution provide the median, 25th
380 and 75th percentiles. Whisker lines indicate minimum and maximum regret values. The regret score
381 represents the difference in syringe sharing reduction for each of the four spatial provider distributions,
382 relative to the spatial distribution with the largest reduction in syringe sharing, for all combinations of
383 reasonable access assumptions. A decision regret score of zero represents an ideal outcome in that the
384 spatial distribution was best at reducing syringe sharing for a given reasonable access assumption.
385 Conversely, a high regret score means that the scenario had a significantly larger number of syringe
386 sharing episodes relative to the best scenario with the fewest number of syringe sharing episodes.
387
388

389 Figure 3 therefore helps to provide insight as to how reasonable access assumptions impact individuals'
390 decisions to initiate and continue methadone treatment. The need-based 2 distribution (PWID density)
391 performs better than the need-based 1 (total population density) and actual distributions when spatial
392 access to providers is important (i.e., low travel distance preference and higher barriers to travel,
393 represented as orange dots). The need-based 1 distribution performs better than the need-based 2 and
394 actual distributions under medium and high travel distance preference (e.g. willingness to travel further
395 and lesser barriers to travel, represented as blue and green dots).

396
397 The actual provider distribution results in a greater reduction in syringe sharing events than the need-
398 based 2 distribution (PWID density) only when assuming a high travel distance preference (green dots),
399 while it performs much worse than both need-based distributions when assuming low travel distance
400 preference (orange dots). Notably, the actual provider distribution does not achieve a zero (best) regret
401 score for any combination of reasonable access assumptions (Figure 3). In all cases, the spatially random
402 distribution generates the worst result (Figure 3).

403
404 Based on a 75th percentile regret metric for each of the four spatial provider distributions, the Need-based
405 2 spatial distribution (PWID density) represents a more robust distribution of methadone providers with
406 respect to reducing annual syringe sharing events, across the uncertainties around all reasonable access
407 assumptions and travel distance preferences (Figure 3, fourth column).

408
409 **DISCUSSION**

410 Our agent-based modeling study of PWID from Chicago and the surrounding Illinois suburbs provides
411 valuable insights into the development of future interventions to enhance MOUD treatment uptake by
412 PWID. We found that the impact of the spatial distribution of methadone providers on syringe sharing

413 frequency is dependent on assumptions of access. When there is a low travel distance preference for
414 accessing methadone providers, i.e., PWID are faced with significant structural barriers, distributing
415 providers near areas that have the greatest need (defined by density of PWID) is optimal (Figure 3).
416 However, this strategy also decreases access across suburban locales, posing even greater difficulty in
417 regions with fewer transit options and providers (Figure 2). As such, without an adequate number of
418 providers to give equitable coverage across the region, spatial redistribution cannot be optimized to
419 provide equitable access to all persons (and potential persons) with OUD. Policies that would expand
420 geographic access to methadone maintenance treatment by making it available at pharmacies and/or
421 federally qualified health centers may better meet the need of this population [15,46,47], and are
422 currently an area of vigorous debate and consideration [5].

423

424 The PWID population in Chicago and the surrounding suburbs [48] and other urban areas [35] is well-
425 characterized. Detailed and current knowledge on PWID demographics can be used to study how access
426 to MOUD treatment providers can be improved over existing resource distributions, along with estimates
427 of future needs due to shifts in PWID demographics and locations.

428

429 For all reasonable access assumptions and provider location distributions, spatially redistributing
430 methadone providers relative to the actual distribution may effectively decrease access in some areas.
431 There were no scenarios that exhibited zero areas with worse access compared to the actual scenario,
432 highlighting the scarcity of providers in the region as a major challenge. Geospatial visualization of our
433 simulation results (Figures 1 and 2) show that the more remote and less populated areas remained
434 inaccessible, reflecting urban-suburban accessibility challenges. Underserved areas could be
435 supplemented with mobile treatment providers to target these vulnerable populations.

436

437 Under modeling scenarios with substantial uncertainties as in the current study, particularly related to
438 underlying individual behaviors that are difficult to observe, optimizing spatial provider distributions to
439 reduce syringe sharing among PWID may not be an appropriate goal. Instead, robust [29] methadone
440 provider location distributions that perform well over a wide range of possible ground truths and
441 uncertainties should be sought. Detailed, data-driven, agent-based models combined with the capacity
442 for large-scale computational experimentation, can provide such analyses to support decision making
443 under uncertainties, or when empirical data collection is costly or unethical. Our results show that the
444 Need-based 2 spatial distribution (PWID density) represents the most robust distribution of methadone
445 providers with respect to reducing annual syringe sharing events, across the uncertainties around all
446 reasonable access assumptions and travel distance preferences (Figure 3, fourth column).

447
448 Need-based counterfactuals were more like the actual provider distribution than the spatially random
449 distribution, suggesting that some areas' needs for methadone providers are being met. However, some
450 geographic locales remain in high need of providers, as demonstrated by the need-based scenarios
451 (Figures 1 and 2). McHenry county, in the northeastern part of the study area, is notable for having all or
452 most of its zip codes characterized by no access in all travel distance preference assumptions – despite a
453 large PWID population in need of MOUD treatment options. Many nearby suburban counties likewise
454 have a patchwork of access across travel distance preference assumptions. While some regions of Chicago
455 have access to providers, more access on transit-connected northern and lake coastal sides of the city
456 would better support populations who currently need, or may need, treatment.

457
458 The low travel distance preference assumption highlights multiple, significant gaps in access across the
459 Chicago area and surrounding suburban counties. While this assumption may seem restrictive, it may also
460 be the most realistic. For example, 1- and 5-miles traveled in urban or suburban areas for a resource

461 required daily or weekly is considered exceptionally reasonable in food access literature (where grocery
462 stores may also be accessed weekly). This low travel distance preference assumption may also be
463 optimistic because of additional social, economic, and structural barriers faced at opioid treatment
464 programs providing methadone services, like cost and drug use stigma (experienced at the provider
465 and/or neighborhood that it is located within). Our study has important implications for guiding policy
466 toward improving access to MOUD among PWID, particularly in areas where the population is dispersed,
467 e.g., expansive suburban areas in large metropolitan cities like Chicago.

468

469 **Limitations**

470 Our current results report reductions in annual syringe sharing events for all combinations of reasonable
471 access assumption and provider spatial distributions. Downstream health sequelae such as hepatitis C and
472 HIV have been examined in previous work [2,49] in the PWID population; however, the current study did
473 not show significant associated reductions in HCV infection in most zip codes, even as the number of
474 syringe sharing events are reduced compared to baseline (data not shown). The most likely explanation is
475 that since the current study does not implement HCV treatment and other harm reduction services (e.g.,
476 sterile syringe and equipment provision), simply reducing the syringe sharing frequency in a highly
477 connected PWID network is not sufficient to eliminate new HCV infection without also reducing the
478 disease incidence.

479 Second, the reported results include the annual reduction in syringe sharing for only a single simulation
480 year (2030). Time-varying trends in syringe sharing metrics were not investigated. Further, the PWID
481 population is maintained at a constant size of 32,000 individuals for the course of the simulation. Although
482 we model transient changes in PWID demographics as in previous studies [2,30], we believe that the PWID
483 population size may be somewhat close to constant given that people who transition to MOUDs is
484 balanced out by new initiates into injection drug use entering the population.

485

486 **Acknowledgements**

487 This work is supported by the National Institute on Drug Abuse (NIH) grant U2CDA050098 (The
488 Methodology and Advanced Analytics Resource Center), by the National Institute of General Medical
489 Sciences grant R01GM121600, by the National Institute of Allergy and Infectious Diseases (NIH) grant
490 R01AI158666, by the National Institute on Drug Abuse (NIH) grant R01DA043484, and by the U.S.
491 Department of Energy under contract number DE-AC02-06CH11357, and was completed with resources
492 provided by the Laboratory Computing Resource Center at Argonne National Laboratory (Bebop cluster).
493 The research presented in this paper is that of the authors and does not necessarily reflect the position
494 or policy of the National Institute on Drug Abuse or any other organization.

495 REFERENCES

- 496 1. Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, et al. The contribution of injection
497 drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling
498 study. *Lancet Gastroenterol Hepatol*. 2019;4: 435–444. doi:10.1016/S2468-1253(19)30085-8
- 499 2. Tatara E, Gutfraind A, Collier NT, Echevarria D, Cotler SJ, Major ME, et al. Modeling hepatitis C
500 micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan
501 Chicago. *PLOS ONE*. 2022;17: e0264983. doi:10.1371/journal.pone.0264983
- 502 3. Tatara E, Schneider J, Quasebarth M, Collier N, Pollack H, Boodram B, et al. Application of
503 Distributed Agent-based Modeling to Investigate Opioid Use Outcomes in Justice Involved
504 Populations. 2021 IEEE International Parallel and Distributed Processing Symposium Workshops
505 (IPDPSW). 2021. pp. 989–997. doi:10.1109/IPDPSW52791.2021.00157
- 506 4. Williams LD, Mackesy-Amiti ME, Latkin C, Boodram B. Drug use-related stigma, safer injection
507 norms, and hepatitis C infection among a network-based sample of young people who inject drugs.
508 *Drug Alcohol Depend*. 2021;221: 108626. doi:10.1016/j.drugalcdep.2021.108626
- 509 5. Meyerson BE. Opportunities and Challenges: Hepatitis C Testing and Treatment Access Experiences
510 Among People in Methadone and Buprenorphine Treatment During COVID-19, Arizona, 2021. 2023.
- 511 6. Andraka-Christou B. Addressing Racial And Ethnic Disparities In The Use Of Medications For Opioid
512 Use Disorder. *Health Aff (Millwood)*. 2021;40: 920–927. doi:10.1377/hlthaff.2020.02261
- 513 7. Meyerson BE, Bentele KG, Russell DM, Brady BR, Downer M, Garcia RC, et al. Nothing really
514 changed: Arizona patient experience of methadone and buprenorphine access during COVID. *PLOS*
515 *ONE*.
- 516 8. Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health
517 Indicators in the United States: Results from the 2020 National Survey on Drug Use and Health.
518 2021. Available: <https://www.samhsa.gov/data>
- 519 9. Gryczynski J, Schwartz RP, Salkever DS, Mitchell SG, Jaffe JH. Patterns in admission delays to
520 outpatient methadone treatment in the United States. *J Subst Abuse Treat*. 2011;41: 431–439.
521 doi:10.1016/j.jsat.2011.06.005
- 522 10. Laroche MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for Opioid Use
523 Disorder After Nonfatal Opioid Overdose and Association With Mortality. *Ann Intern Med*.
524 2018;169: 137–145. doi:10.7326/M17-3107
- 525 11. Joudrey PJ, Edelman EJ, Wang EA. Methadone for Opioid Use Disorder—Decades of Effectiveness
526 but Still Miles Away in the US. *JAMA Psychiatry*. 2020;77: 1105.
527 doi:10.1001/jamapsychiatry.2020.1511
- 528 12. Yarborough BJH, Stumbo SP, McCarty D, Mertens J, Weisner C, Green CA. Methadone,
529 buprenorphine and preferences for opioid agonist treatment: A qualitative analysis. *Drug Alcohol*
530 *Depend*. 2016;160: 112–118. doi:10.1016/j.drugalcdep.2015.12.031

- 531 13. Bosanac EM, Parkinson RC, Hall DS. Geographic Access to Hospital Care: A 30-Minute Travel Time
532 Standard: *Med Care*. 1976;14: 616–624. doi:10.1097/00005650-197607000-00006
- 533 14. Brustrom JE, Hunter DC. Going the distance: how far will women travel to undergo free
534 mammography? *Mil Med*. 2001;166: 347–349.
- 535 15. Kleinman RA. Comparison of Driving Times to Opioid Treatment Programs and Pharmacies in the US.
536 *JAMA Psychiatry*. 2020;77: 1163–1171. doi:10.1001/jamapsychiatry.2020.1624
- 537 16. Joudrey PJ, Kolak M, Lin Q, Paykin S, Anguiano V, Wang EA. Assessment of Community-Level
538 Vulnerability and Access to Medications for Opioid Use Disorder. *JAMA Netw Open*. 2022;5:
539 e227028. doi:10.1001/jamanetworkopen.2022.7028
- 540 17. Friedmann PD, Lemon SC, Stein MD. Transportation and retention in outpatient drug abuse
541 treatment programs. *J Subst Abuse Treat*. 2001;21: 97–103. doi:10.1016/s0740-5472(01)00185-4
- 542 18. Knudsen HK, Roman PM. Financial Factors and the Implementation of Medications for Treating
543 Opioid Use Disorders. *J Addict Med*. 2012;6: 280–286. doi:10.1097/ADM.0b013e318262a97a
- 544 19. Elwy AR, Ranganathan G, Eisen SV. Race-ethnicity and diagnosis as predictors of outpatient service
545 use among treatment initiators. *Psychiatr Serv Wash DC*. 2008;59: 1285–1291.
546 doi:10.1176/ps.2008.59.11.1285
- 547 20. Snowden LR, Pingitore D. Frequency and scope of mental health service delivery to African
548 Americans in primary care. *Ment Health Serv Res*. 2002;4: 123–130. doi:10.1023/a:1019709728333
- 549 21. Penchansky R, Thomas JW. The concept of access: definition and relationship to consumer
550 satisfaction. *Med Care*. 1981;19: 127–140. doi:10.1097/00005650-198102000-00001
- 551 22. Biancarelli DL, Biello KB, Childs E, Drainoni M, Salhaney P, Edeza A, et al. Strategies used by people
552 who inject drugs to avoid stigma in healthcare settings. *Drug Alcohol Depend*. 2019;198: 80–86.
553 doi:10.1016/j.drugalcdep.2019.01.037
- 554 23. Talen E, Anselin L. Assessing Spatial Equity: An Evaluation of Measures of Accessibility to Public
555 Playgrounds. *Environ Plan Econ Space*. 1998;30: 595–613. doi:10.1068/a300595
- 556 24. Heil SH, Sigmon SC, Jones HE, Wagner M. Comparison of Characteristics of Opioid-Using Pregnant
557 Women in Rural and Urban Settings. *Am J Drug Alcohol Abuse*. 2008;34: 463–471.
558 doi:10.1080/00952990802122358
- 559 25. Lister JJ, Weaver A, Ellis JD, Himle JA, Ledgerwood DM. A systematic review of rural-specific barriers
560 to medication treatment for opioid use disorder in the United States. *Am J Drug Alcohol Abuse*.
561 2020;46: 273–288. doi:10.1080/00952990.2019.1694536
- 562 26. Rosenblum A, Cleland CM, Fong C, Kayman DJ, Tempalski B, Parrino M. Distance Traveled and Cross-
563 State Commuting to Opioid Treatment Programs in the United States. *J Environ Public Health*.
564 2011;2011: 1–10. doi:10.1155/2011/948789

- 565 27. Ridgway JP, Almirol EA, Schmitt J, Schuble T, Schneider JA. Travel Time to Clinic but not
566 Neighborhood Crime Rate is Associated with Retention in Care Among HIV-Positive Patients. *AIDS*
567 *Behav.* 2018;22: 3003–3008. doi:10.1007/s10461-018-2094-5
- 568 28. Amiri S, Lutz R, Socías ME, McDonnell MG, Roll JM, Amram O. Increased distance was associated with
569 lower daily attendance to an opioid treatment program in Spokane County Washington. *J Subst*
570 *Abuse Treat.* 2018;93: 26–30. doi:10.1016/j.jsat.2018.07.006
- 571 29. Lempert RJ. Robust Decision Making (RDM). In: Marchau VAWJ, Walker WE, Bloemen PJTM, Popper
572 SW, editors. *Decision Making under Deep Uncertainty: From Theory to Practice*. Cham: Springer
573 International Publishing; 2019. pp. 23–51. doi:10.1007/978-3-030-05252-2_2
- 574 30. Gutfraind A, Boodram B, Prachand N, Hailegiorgis A, Dahari H, Major ME. Agent-Based Model
575 Forecasts Aging of the Population of People Who Inject Drugs in Metropolitan Chicago and Changing
576 Prevalence of Hepatitis C Infections. Kaderali L, editor. *PLOS ONE*. 2015;10: e0137993.
577 doi:10.1371/journal.pone.0137993
- 578 31. Huo D, Ouellet LJ. Needle exchange and injection-related risk behaviors in Chicago: a longitudinal
579 study. *J Acquir Immune Defic Syndr* 1999. 2007;45: 108–114. doi:10.1097/QAI.0b013e318050d260
- 580 32. Lansky A, Abdul-Quader AS, Cribbin M, Hall T, Finlayson TJ, Garfein RS, et al. Developing an HIV
581 Behavioral Surveillance System for Injecting Drug Users: The National HIV Behavioral Surveillance
582 System. *Public Health Rep.* 2007;122: 48–55.
- 583 33. Mackesy-Amiti ME, Boodram B, Spiller MW, Paz-Bailey G, Prachand N, Broz D, et al. Injection-
584 Related Risk Behavior and Engagement in Outreach, Intervention and Prevention Services Across 20
585 US Cities. *J Acquir Immune Defic Syndr.* 2017;75 Suppl 3: S316–S324.
586 doi:10.1097/QAI.0000000000001406
- 587 34. Boodram B, Mackesy-Amiti M-E, Latkin C. The role of social networks and geography on risky
588 injection behaviors of young persons who inject drugs. *Drug Alcohol Depend.* 2015;154: 229–235.
589 doi:10.1016/j.drugalcdep.2015.06.042
- 590 35. Tempalski B, Pouget ER, Cleland CM, Brady JE, Cooper HLF, Hall HI, et al. Trends in the Population
591 Prevalence of People Who Inject Drugs in US Metropolitan Areas 1992–2007. Khudyakov YE, editor.
592 *PLoS ONE*. 2013;8: e64789. doi:10.1371/journal.pone.0064789
- 593 36. Boodram B, Hotton AL, Shekhtman L, Gutfraind A, Dahari H. High-Risk Geographic Mobility Patterns
594 among Young Urban and Suburban Persons who Inject Drugs and their Injection Network Members.
595 *J Urban Health Bull N Y Acad Med.* 2018;95: 71–82. doi:10.1007/s11524-017-0185-7
- 596 37. Corsi KF, Lehman WK, Booth RE. The effect of methadone maintenance on positive outcomes for
597 opiate injection drug users. *J Subst Abuse Treat.* 2009;37: 120–126. doi:10.1016/j.jsat.2008.11.004
- 598 38. Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative
599 Effectiveness of Different Treatment Pathways for Opioid Use Disorder. *JAMA Netw Open.* 2020;3:
600 e1920622. doi:10.1001/jamanetworkopen.2019.20622

- 601 39. Pebesma E. Simple Features for R: Standardized Support for Spatial Vector Data. *R J.* 2018;10: 439–
602 446.
- 603 40. Blanchard T, Matthews T. Retail Concentration, Food Deserts, and Food Disadvantaged
604 Communities in Rural America. *Remaking the North American Food System: Strategies for*
605 *Sustainability.* University of Nebraska Press; 2009.
- 606 41. Jiao J, Moudon AV, Ulmer J, Hurvitz PM, Drewnowski A. How to Identify Food Deserts: Measuring
607 Physical and Economic Access to Supermarkets in King County, Washington. *Am J Public Health.*
608 2012;102: e32–e39. doi:10.2105/AJPH.2012.300675
- 609 42. Schmitt SK, Phibbs CS, Piette JD. The influence of distance on utilization of outpatient mental health
610 aftercare following inpatient substance abuse treatment. *Addict Behav.* 2003;28: 1183–1192.
611 doi:10.1016/S0306-4603(02)00218-6
- 612 43. Home - SAMHSA Behavioral Health Treatment Services Locator. [cited 2 May 2022]. Available:
613 <https://findtreatment.samhsa.gov/>
- 614 44. US Census Bureau CHS. Methods of Apportionment - History - U.S. Census Bureau. [cited 3 Oct
615 2023]. Available:
616 https://www.census.gov/history/www/reference/apportionment/methods_of_apportionment.html
- 617 45. Ozik J, Collier NT, Wozniak JM, Spagnuolo C. From desktop to Large-Scale Model Exploration with
618 Swift/T. 2016 Winter Simulation Conference (WSC). 2016. pp. 206–220.
619 doi:10.1109/WSC.2016.7822090
- 620 46. Iloglu S, Joudrey PJ, Wang EA, Thornhill TA, Gonsalves G. Expanding access to methadone treatment
621 in Ohio through federally qualified health centers and a chain pharmacy: A geospatial modeling
622 analysis. *Drug Alcohol Depend.* 2021;220: 108534. doi:10.1016/j.drugalcdep.2021.108534
- 623 47. Joudrey PJ, Edelman EJ, Wang EA. Methadone for Opioid Use Disorder-Decades of Effectiveness but
624 Still Miles Away in the US. *JAMA Psychiatry.* 2020;77: 1105–1106.
625 doi:10.1001/jamapsychiatry.2020.1511
- 626 48. Boodram B, Mackesy-Amity ME, Khanna A, Brickman B, Dahari H, Ozik J. People who inject drugs in
627 metropolitan Chicago: A meta-analysis of data from 1997-2017 to inform interventions and
628 computational modeling toward hepatitis C microelimination. *PLOS ONE.* 2022;17: e0248850.
629 doi:10.1371/journal.pone.0248850
- 630 49. Tsang MA, Schneider JA, Sypsa V, Schumm P, Nikolopoulos GK, Paraskevis D, et al. Network
631 Characteristics of People Who Inject Drugs Within a New HIV Epidemic Following Austerity in
632 Athens, Greece. *JAIDS J Acquir Immune Defic Syndr.* 2015;69: 499.
633 doi:10.1097/QAI.0000000000000665
- 634
635

636 **Supporting Information**

637

638 **Table S1. Overall syringe sharing reduction and regret scores under for each reasonable access**
 639 **assumption under each scenario.**

640

Overall Needle Sharing Reduction (Enrollment 90% compared to Enrollment 0%) & Regret Scores														
Threshold	Penalty	Max dist threshold		Needle sharing reduction					Best (max)	Regret score				
				Actual	S1	S2	S3			RS_Actual	RS_S1	RS_S2	RS_S3	
1/5	0.6	F	870K	429K	429K	943K	1,013K	1,013K	143K	584K	70K	0K	0K	
1/5	0.6	T	870K	429K	429K	943K	1,016K	1,016K	146K	587K	73K	0K	0K	
1/5	0.75	F	895K	486K	486K	972K	1,043K	1,043K	148K	557K	71K	0K	0K	
1/5	0.75	T	902K	486K	486K	972K	1,034K	1,034K	132K	548K	62K	0K	0K	
1/5	0.9	F	985K	656K	656K	1,036K	1,097K	1,097K	112K	441K	61K	0K	0K	
1/5	0.9	T	980K	656K	656K	1,036K	1,087K	1,087K	107K	431K	51K	0K	0K	
2/10	0.6	F	1,014K	713K	713K	1,108K	1,050K	1,108K	94K	395K	0K	58K	58K	
2/10	0.6	T	1,007K	713K	713K	1,108K	1,062K	1,108K	101K	395K	0K	46K	46K	
2/10	0.75	F	1,016K	734K	734K	1,120K	1,063K	1,120K	103K	385K	0K	57K	57K	
2/10	0.75	T	1,020K	734K	734K	1,120K	1,063K	1,120K	100K	385K	0K	56K	56K	
2/10	0.9	F	1,050K	823K	823K	1,117K	1,078K	1,117K	66K	294K	0K	39K	39K	
2/10	0.9	T	1,045K	823K	823K	1,117K	1,076K	1,117K	72K	294K	0K	41K	41K	
5/20	0.6	F	1,059K	807K	807K	1,073K	1,042K	1,073K	14K	266K	0K	30K	30K	
5/20	0.6	T	1,061K	807K	807K	1,073K	1,044K	1,073K	11K	266K	0K	29K	29K	
5/20	0.75	F	1,062K	826K	826K	1,079K	1,052K	1,079K	17K	254K	0K	27K	27K	
5/20	0.75	T	1,071K	826K	826K	1,079K	1,047K	1,079K	8K	254K	0K	32K	32K	
5/20	0.9	F	1,065K	896K	896K	1,083K	1,060K	1,083K	18K	187K	0K	23K	23K	
5/20	0.9	T	1,072K	896K	896K	1,083K	1,053K	1,083K	10K	187K	0K	30K	30K	
75th percentile RS									111K	439K	58K	40K	40K	

641

642

643 Table S1 shows the syringe sharing reduction outcome for each reasonable access assumption under
 644 each scenario, along with regret scores. For example, when the ideal geographical travel distance
 645 preference is set to be low (i.e., 1 mile for urban and 5 miles for suburban), penalty equals to 0.6, and
 646 we do not set a maximum limit, Scenario 3 (Need-based 2) generates the most syringe sharing reduction
 647 (1,013K, see first row in Table S1). Accordingly, the regret score for each other scenario is the difference
 648 between their syringe sharing reduction result and Scenario 3 (Need-based 2). In this case, Scenario 1
 649 (spatially random) generates the largest regret score, meaning we expect the syringe sharing reduction
 650 to be the lowest in this case. In the last row of Table S1, we report the 75th percentile of regret scores
 651 across each of the 18 reasonable access assumptions for each scenario, from which we observe that the
 652 two *Need-based* scenarios (Scenario 2 and Scenario 3) perform the best. Notably, the *Actual* scenario
 653 performs worse than the two *Need-based* scenarios but better than the *Random* scenario.

654

655

656 **Table S2. Overall syringe sharing reduction relative risk and regret scores for each reasonable access**
 657 **assumption under each scenario.**
 658

Overall Needle Sharing Reduction Relative Risk (Enrollment 90%/Enrollment 0%, zip code weighted by Enrollment 0%)													
exp	Penalty	Threshold	Actual	S1	S2	S3	Best (min)	RS_Actual	RS_S1	RS_S2	RS_S3		
1	0.6	1/5	0.567	0.786	0.530	0.495	0.495	0.071	0.291	0.035	0.000		
2	0.6	2/10	0.495	0.645	0.448	0.477	0.448	0.047	0.197	0.000	0.029		
3	0.6	5/20	0.472	0.598	0.466	0.481	0.466	0.007	0.132	0.000	0.015		
4	0.75	1/5	0.554	0.758	0.516	0.480	0.480	0.074	0.278	0.035	0.000		
5	0.75	2/10	0.494	0.634	0.442	0.470	0.442	0.052	0.192	0.000	0.028		
6	0.75	5/20	0.471	0.589	0.462	0.476	0.462	0.009	0.126	0.000	0.014		
7	0.9	1/5	0.509	0.673	0.484	0.453	0.453	0.056	0.220	0.030	0.000		
8	0.9	2/10	0.477	0.590	0.444	0.463	0.444	0.033	0.146	0.000	0.019		
9	0.9	5/20	0.469	0.554	0.461	0.472	0.461	0.009	0.093	0.000	0.011		
10	0.6	1/5	0.567	0.786	0.530	0.494	0.494	0.073	0.293	0.036	0.000		
11	0.6	2/10	0.498	0.645	0.448	0.471	0.448	0.050	0.197	0.000	0.023		
12	0.6	5/20	0.471	0.598	0.466	0.480	0.466	0.006	0.132	0.000	0.014		
13	0.75	1/5	0.550	0.758	0.516	0.485	0.485	0.066	0.273	0.031	0.000		
14	0.75	2/10	0.492	0.634	0.442	0.470	0.442	0.050	0.192	0.000	0.028		
15	0.75	5/20	0.466	0.589	0.462	0.478	0.462	0.004	0.126	0.000	0.016		
16	0.9	1/5	0.512	0.673	0.484	0.459	0.459	0.053	0.215	0.025	0.000		
17	0.9	2/10	0.479	0.590	0.444	0.464	0.444	0.036	0.146	0.000	0.020		
18	0.9	5/20	0.466	0.554	0.461	0.475	0.461	0.005	0.093	0.000	0.015		
							75th percentile RS	0.055	0.219	0.029	0.020		0.020

Note. RS represents regret score.

659